Related references
Note: Only part of the references are listed.8-Hydroxyquinoline-based inhibitors of the Rce1 protease disrupt Ras membrane localization in human cells
Idrees Mohammed et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2016)
Molecular mechanisms linking geranylgeranyl diphosphate synthase to cell survival and proliferation
Sherry S. Agabiti et al.
MOLECULAR MEMBRANE BIOLOGY (2016)
Novel α-substituted tropolones promote potent and selective caspase-dependent leukemia cell apoptosis
Jin Li et al.
PHARMACOLOGICAL RESEARCH (2016)
Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?
Adrienne D. Cox et al.
CLINICAL CANCER RESEARCH (2015)
Protein Prenylation: Enzymes, Therapeutics, and Biotechnology Applications
Charuta C. Palsuledesai et al.
ACS CHEMICAL BIOLOGY (2015)
Synthesis of a Phosphoantigen Prodrug that Potently Activates Vγ9Vδ2 T-Lymphocytes
Chia-Hung Christine Hsiao et al.
CHEMISTRY & BIOLOGY (2014)
Cyclopropene Cycloadditions with Annulated Furans: Total Synthesis of (+)- and (-)-Frondosin B and (+)-Frondosin A
E. Zachary Oblak et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2014)
Zoledronic acid induces apoptosis and S-phase arrest in mesothelioma through inhibiting Rab family proteins and topoisomerase II actions
S. Okamoto et al.
CELL DEATH & DISEASE (2014)
Management of bone disease in multiple myeloma
Evangelos Terpos et al.
EXPERT REVIEW OF HEMATOLOGY (2014)
The focal adhesion kinase inhibitor PF-562,271 impairs primary CD4+T cell activation
Andrew J. Wiemer et al.
BIOCHEMICAL PHARMACOLOGY (2013)
Nitrogen-containing bisphosphonates induce apoptosis of hematopoietic tumor cells via inhibition of Ras signaling pathways and Bim-mediated activation of the intrinsic apoptotic pathway
Masanobu Tsubaki et al.
BIOCHEMICAL PHARMACOLOGY (2013)
Geranylgeranyltransferase I Promotes Human Glioma Cell Growth through Rac1 Membrane Association and Activation
Xiuping Zhou et al.
JOURNAL OF MOLECULAR NEUROSCIENCE (2013)
Deciphering the signaling networks underlying simvastatin-induced apoptosis in human cancer cells: evidence for non-canonical activation of RhoA and Rac1 GTPases
Y. Zhu et al.
CELL DEATH & DISEASE (2013)
HMG-CoA reductase inhibitors induce apoptosis of lymphoma cells by promoting ROS generation and regulating Akt, Erk and p38 signals via suppression of mevalonate pathway
X-F Qi et al.
CELL DEATH & DISEASE (2013)
Evaluation of substrate and inhibitor binding to yeast and human isoprenylcysteine carboxyl methyltransferases (Icmts) using biotinylated benzophenone-containing photoaffinity probes
Kalub Hahne et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2012)
Adjuvant bisphosphonates: a new standard of care?
Michael Gnant
CURRENT OPINION IN ONCOLOGY (2012)
Bisphosphonates in preclinical bone oncology
Philippe Clezardin et al.
BONE (2011)
The relationship between the chemistry and biological activity of the bisphosphonates
Frank H. Ebetino et al.
BONE (2011)
Geranylgeranyl Diphosphate Synthase: An Emerging Therapeutic Target
A. J. Wiemer et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Bisphosphonates Induce Autophagy by Depleting Geranylgeranyl Diphosphate
Brian M. Wasko et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation
Andreas Guenther et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
How Do Bisphosphonates Inhibit Bone Metastasis In Vivo?
Pierrick G. Fournier et al.
NEOPLASIA (2010)
The Intermediate Enzymes of Isoprenoid Metabolism as Anticancer Targets
Andrew J. Wiemer et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2009)
Context-Dependent Substrate Recognition by Protein Farnesyltransferase
James L. Hougland et al.
BIOCHEMISTRY (2009)
Lowering Bone Mineral Affinity of Bisphosphonates as a Therapeutic Strategy to Optimize Skeletal Tumor Growth Inhibition In vivo
Pierrick G. J. Fournier et al.
CANCER RESEARCH (2008)
Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy
R. G. G. Russell et al.
OSTEOPOROSIS INTERNATIONAL (2008)
Inhibition of geranylgeranyl diphosphate synthase induces apoptosis through multiple mechanisms and displays synergy with inhibition of other isoprenoid biosynthetic enzymes
Amel Dudakovic et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Bisphosphonates target multiple sites in both cis- and trans-prenyltransferases
Rey-Ting Guo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
GGTase-I deficiency reduces tumor formation and improves survival in mice with K-RAS-induced lung cancer
Anna-Karin M. Sjogren et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Inhibitors of the mevalonate pathway as potential therapeutic agents in multiple myeloma
Cindy Baulch-Brown et al.
LEUKEMIA RESEARCH (2007)
Digeranyl bisphosphonate inhibits geranylgeranyl pyrophosphate synthase
Andrew J. Wiemer et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
Bisphosphonate incadronate inhibits growth of human T-cell leukaemia virus type I-infected T-cell lines and primary adult T-cell leukaemia cells by interfering with the mevalonate pathway
Chie Ishikawa et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Molecular mechanisms of action of bisphosphonates: Current status
Anke J. Roelofs et al.
CLINICAL CANCER RESEARCH (2006)
Synthesis and biological activity of isoprenoid bisphosphonates
Larry W. Shull et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2006)
The molecular mechanism of nitrogen-containing bisphosphonates as anti osteoporosis drugs
Kathryn L. Kavanagh et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Bisphosphonates for malignancy-related bone disease: current status, future developments
JJ Body
SUPPORTIVE CARE IN CANCER (2006)
RAS-blocking bisphosphonate zoledronic acid inhibits the abnormal proliferation and differentiation of juvenile myelomonocytic leukemia cells in vitro
Y Ohtsuka et al.
BLOOD (2005)
Zoledronate inhibits proliferation and induces apoptosis of imatinib- resistant chronic myeloid leukaemia cells
C Chuah et al.
LEUKEMIA (2005)
Zoledronate synergises with imatinib mesylate to inhibit Ph+ primary leukaemic cell growth
H Segawa et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Discovery, clinical development, and therapeutic uses of bisphosphonates
AA Licata
ANNALS OF PHARMACOTHERAPY (2005)
Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis
JH Wu et al.
CANCER RESEARCH (2004)
Zoledronic acid up-regulates bone sialoprotein expression in osteoblastic cells through Rho GTPase inhibition
ML Chaplet et al.
BIOCHEMICAL JOURNAL (2004)
Inhibition of isoprene biosynthesis pathway enzymes by phosphonates, bisphosphonates, and diphosphates
F Cheng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines
S Kimura et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2004)
Apoptosis-inducing effect of a new bisphosphonate, YM529, on various hematopoietic tumor cell lines
S Nishida et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2003)
Requirement for ERK activation in cisplatin-induced apoptosis
XT Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)